Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 6:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 1,095 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Volume Control Clear all
Recruiting Not applicable Interventional

Exposure-Based CBT for Avoidant/Restrictive Food Intake in Functional Dyspepsia

NCT05587127
View directory record Official record
Conditions
Avoidant/Restrictive Food Intake Disorder, Dyspepsia, Feeding and Eating Disorders, Cognitive Behavioral Therapy, Appetite Regulation, Functional Dyspepsia, Post-prandial Distress Syndrome, Behavioral Medicine
Interventions
Cognitive Behavioral Therapy
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Oct 28, 2026, 6:52 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Myocardial Perfusion and Fibrosis in Cancer Survivors

NCT03191461
View directory record Official record
Conditions
Myocardial Fibrosis, Myocardial Injury, Chemotherapeutic Toxicity
Interventions
Adenosine stress test MRI
Diagnostic Test
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
21 Years to 85 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2024
U.S. locations
2
States / cities
Winston-Salem, North Carolina • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Oct 28, 2026, 6:52 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Determining the Impact of Emotive Intelligent Spaces

NCT04836286
View directory record Official record
Conditions
Color Perception
Interventions
Emotive Intelligent Spaces (EIS)
Behavioral
Lead sponsor
University of Idaho
Other
Eligibility
3 Years to 6 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Moscow, Idaho
Source: ClinicalTrials.gov public record
Updated Nov 3, 2022 · Synced Oct 28, 2026, 6:52 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Long-acting Biomedical HIV Prevention in Transgender Women

NCT03856580
View directory record Official record
Conditions
HIV Prevention, Transgender Women
Interventions
Alternative long-acting PrEP injection strategies, mHealth adherence app
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 4, 2024 · Synced Oct 28, 2026, 6:52 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of CBL-514 Compared to Placebo in Participants With Dercum's Disease Lipomas

NCT06303570
View directory record Official record
Conditions
Dercum's Disease
Interventions
CBL-514 injection, 0.9% Sodium chloride
Drug
Lead sponsor
Caliway Biopharmaceuticals Co., Ltd.
Industry
Eligibility
18 Years to 64 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 28, 2026, 6:52 AM EDT
Completed Early Phase 1 Interventional

Intraoperative Ketamine for Patients Undergoing Total Joint Arthroplasty

NCT04437888
View directory record Official record
Conditions
Pain, Postoperative, Arthroplasty Complications
Interventions
Ketamine
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Sep 27, 2024 · Synced Oct 28, 2026, 6:52 AM EDT
Completed Phase 4 Interventional Results available

TAP Block Catheters vs Liposomal Bupivacaine for Pain Control After Colorectal Surgery

NCT03080142
View directory record Official record
Conditions
Colorectal Surgery, TAP Blocks
Interventions
Exparel, Ropivacaine
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 90 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Oct 28, 2026, 6:52 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluation of the Aurora Xi New Nomogram Software 2.0

NCT06122935
View directory record Official record
Conditions
Apheresis Related Hypotension
Interventions
Aurora Xi New Nomogram Software 2.0, Aurora Xi Currently Approved Software 1.3
Device
Lead sponsor
Fenwal, Inc.
Industry
Eligibility
18 Years and older
Enrollment
6,735 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
3
States / cities
Lakeland, Florida • West Des Moines, Iowa • American Fork, Utah
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 28, 2026, 6:52 AM EDT
Not yet recruiting Phase 2 Interventional

Single-dose Prophylactic INdomethacin in Extremely Preterm Infants

NCT06572917
View directory record Official record
Conditions
Extreme Prematurity, Intraventricular Hemorrhage, Morbidity;Newborn
Interventions
Indomethacin, Placebo
Drug
Lead sponsor
University of British Columbia
Other
Eligibility
0 Hours to 12 Hours
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
5
States / cities
Roseville, California • Sacramento, California • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Oct 28, 2026, 6:52 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Study to Evaluate Safety and Efficacy of ALX-0061 in Subjects With Systemic Lupus Erythematosus

NCT02437890
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
ALX-0061, Placebo
Biological
Lead sponsor
Ablynx, a Sanofi company
Industry
Eligibility
18 Years to 64 Years
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
28
States / cities
Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Oct 28, 2026, 6:52 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Study to Evaluate the Safety of a Monovalent Vaccine of a New 6:2 Reassortant in Healthy Adults (AV024)

NCT00240877
View directory record Official record
Conditions
Influenza
Interventions
AV024, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
330 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2004
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 20, 2008 · Synced Oct 28, 2026, 6:52 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Investigate the Neuroprotective Effect of PROCRIT (Epoetin Alfa) Versus Placebo in Cancer Patients Who Develop Chemotherapy-induced Peripheral Neuropathy

NCT00267007
View directory record Official record
Conditions
Peripheral Neuropathy, Chemotherapy-induced
Interventions
PROCRIT 40,000 IU QW, Placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
28
States / cities
Mobile, Alabama • Little Rock, Arkansas • Alhambra, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2014 · Synced Oct 28, 2026, 6:52 AM EDT
Completed Phase 2 Interventional Results available

A Comparison of Crotalinae Equine Immune F(ab)2 Antivenom (Anavip) and Crotalidae Polyvalent Immune Fab,

NCT00868309
View directory record Official record
Conditions
Snake Bite, Blood Coagulation Disorders
Interventions
Anavip, CroFab
Biological
Lead sponsor
Instituto Bioclon S.A. de C.V.
Industry
Eligibility
18 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 18, 2016 · Synced Oct 28, 2026, 6:52 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH)

NCT04565717
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis, NASH
Interventions
ALN-HSD, Placebo
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
7
States / cities
Fleming Island, Florida • Marrero, Louisiana • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated May 17, 2024 · Synced Oct 28, 2026, 6:52 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

High-fat Meal Challenge in Pediatrics

NCT05230433
View directory record Official record
Conditions
Pediatric Obesity, Insulin Resistance
Interventions
High-fat Challenge
Dietary Supplement
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
8 Years to 17 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Oct 28, 2026, 6:52 AM EDT
Not yet recruiting Not applicable Interventional

Mechanical Ventilator Adjustments and Patient Dyspnea

NCT07701850
View directory record Official record
Conditions
Respiratory Failure, Dyspnea During Mechanical Ventilation, Mechanical Ventilation
Interventions
Change to VC/AC, Change in Tidal Volume, Change in inspiratory flow, Change in PEEP, Change to PSV
Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 28, 2026, 6:52 AM EDT
Active, not recruiting Phase 2 Interventional

Treatment of ARDS With Instilled T3

NCT04115514
View directory record Official record
Conditions
ARDS, Human, Lung, Wet, Thyroid, Pulmonary Edema, Lung Inflammation
Interventions
Liothyronine Sodium (T3+0.9% sodium chloride) modified formulation specifically for airway instillation., Non-intervention
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
2
States / cities
Edina, Minnesota • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 28, 2026, 6:52 AM EDT
Recruiting Not applicable Interventional

Blood Pressure Slopes and Ultrafiltration in Hemodialysis Patients

NCT04163614
View directory record Official record
Conditions
End Stage Renal Disease, Hypertension, Extracellular Volume Overload, Intradialytic Hypotension
Interventions
IBPS-Guided Ultrafiltration
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 28, 2026, 6:52 AM EDT
Completed Phase 3 Interventional

Phase III Lucanix™ Vaccine Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Following Front-line Chemotherapy

NCT00676507
View directory record Official record
Conditions
Lung Neoplasm, Carcinoma Non-small Cell Lung Cancer Stage IIIA, Carcinoma Non-small Cell Lung Cancer Stage IIIB, Carcinoma Non-small Cell Lung Cancer Stage IV
Interventions
Lucanix™, Placebo Comparator
Biological · Other
Lead sponsor
NovaRx Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
532 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
53
States / cities
Mobile, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated May 8, 2015 · Synced Oct 28, 2026, 6:52 AM EDT
Completed Phase 3 Interventional

Study of Plozasiran in Adults With Severe Hypertriglyceridemia

NCT06347016
View directory record Official record
Conditions
Severe Hypertriglyceridemia
Interventions
Plozasiran Injection, Placebo
Drug
Lead sponsor
Arrowhead Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
311 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
50
States / cities
Birmingham, Alabama • Mobile, Alabama • Beverly Hills, California + 44 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 28, 2026, 6:52 AM EDT
Not yet recruiting No phase listed Observational

Outcomes of Different Bone Graft Combinations for Maxillary Sinus Augmentation Procedure

NCT07512011
View directory record Official record
Conditions
Bone Grafting, Sinus Lifting
Interventions
Bone grafting on both sides
Device
Lead sponsor
Ohio State University
Other
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 28, 2026, 6:52 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Alcohol and the Social Brain: An Alcohol-Administration Hyperscanning Study Employing a Within-Subject Design

NCT07125534
View directory record Official record
Conditions
Alcohol Drinking, Alcohol Use Disorder (AUD), Alcohol Intoxication, Alcohol; Harmful Use, Alcoholism, Binge Drinking
Interventions
Alcohol beverage, Control - non alcoholic beverage
Drug · Other
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
21 Years to 30 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
2
States / cities
Champaign, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 29, 2025 · Synced Oct 28, 2026, 6:52 AM EDT
Completed Phase 4 Interventional Results available

Comparing Subsartorial Saphenous Nerve Blocks With and Without Dexamethasone for Anterior Cruciate Ligament Reconstruction

NCT01586806
View directory record Official record
Conditions
Anterior Cruciate Ligament Reconstruction, Regional Anesthesia, Saphenous Nerve Block
Interventions
Bupivacaine Only, Bupivacaine with 1 mg of Dexamethasone, Bupivacaine with 4 mg of Dexamethasone
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
16 Years to 65 Years
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 28, 2016 · Synced Oct 28, 2026, 6:52 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Evaluation of Safety and Efficacy of RZL-012 in Subjects Seeking Fat Reduction in the Flanks

NCT05445557
View directory record Official record
Conditions
Flank Mass
Interventions
RZL-012, Placebo
Drug
Lead sponsor
Raziel Therapeutics Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 28, 2026, 6:52 AM EDT